ESMO 2026: The Next Frontier in CAR T-Cell Therapy
As cellular therapy evolves across multiple myeloma and B-cell lymphoma, ESMO 2026 offers an opportunity to examine a more demanding measure of progress: whether next-generation CAR T-cell designs can translate powerful initial responses into durable disease control, with a treatment experience that is safer and more accessible.
Introduction: A new measure of progress for cellular therapy
CAR T-cell therapy has transformed the management of selected relapsed or refractory haematological malignancies, particularly B-cell cancers and multiple myeloma. By engineering a patient’s own T cells to recognise a target antigen expressed on malignant cells, these therapies can produce deep responses in patients whose disease has progressed after multiple previous lines of treatment.
Their significance, however, extends beyond tumor reduction. In a subset of patients, a single CAR T-cell infusion can induce remissions that persist for years, challenging the traditional assumption that heavily pretreated haematological cancer must be controlled through an indefinite sequence of therapies. The defining question for the field is therefore no longer whether CAR T cells can generate high response rates. It is whether they can deliver remissions that are deep, durable and clinically meaningful while reducing the toxicity, manufacturing burden and access constraints that still limit wider use.
This shift raises a more demanding set of questions. Which CAR design features improve expansion, persistence and tumor control? Does deep response, including minimal residual disease negativity, translate into sustained progression-free and overall survival? Can next-generation constructs preserve efficacy while reducing cytokine-release syndrome, neurotoxicity and prolonged cytopenias? And can increasingly complex cellular products be delivered reliably enough to become a practical component of routine care?
ESMO 2026 provides a useful framework for examining these questions. The programme brings together emerging next-generation CAR T-cell approaches, extended follow-up with anitocabtagene autoleucel in heavily pretreated multiple myeloma, and long-term outcomes with CD19-directed CAR T-cell therapy in relapsed or refractory B-cell non-Hodgkin lymphoma. Together, these data shift attention from response as an isolated endpoint toward a more consequential objective: durable remission supported by appropriate safety, cellular persistence and real-world feasibility.
1. Beyond the target: CAR T-cell engineering enters a new phase
The first generation of successful CAR T-cell therapies established that genetically engineered immune cells can produce substantial clinical activity in selected relapsed or refractory haematological malignancies, including B-cell cancers and multiple myeloma. The next phase of development is focused not only on the antigen a CAR T cell recognises, but also on how the engineered cell binds its target, activates, expands, persists and functions within a biologically hostile disease environment.
Antigen selection is only one determinant of therapeutic performance. The antigen-binding domain, hinge and spacer design, co-stimulatory and intracellular signalling domains, cellular composition, manufacturing process, T-cell fitness, post-infusion expansion and tumor microenvironment can all affect efficacy and toxicity. Consequently, two CAR T-cell products directed against the same target should not automatically be considered interchangeable. Next-generation programmes are therefore refining receptor design, improving T-cell quality and persistence, and addressing barriers such as antigen escape, impaired trafficking, immune suppression and relapse after deep initial response.
As the CAR T-cell landscape becomes more competitive, differentiation will depend on more than headline response rates. The relevant measures include deep response and minimal residual disease negativity, remission durability, progression-free and overall survival, cytokine-release syndrome, neurotoxicity, prolonged cytopenias, manufacturing reliability, time to infusion and real-world feasibility. At ESMO 2026, the key question is not simply which new CAR T-cell candidates are entering the clinic, but whether specific engineering decisions can generate a meaningful and durable clinical advantage that remains credible with mature follow-up and comparative evidence.
2. Anito-cel: Can a different binding domain strengthen the BCMA-directed CAR T-cell proposition?
Multiple myeloma remains an important test case for next-generation cellular therapy. Although BCMA-directed CAR T-cell treatments have demonstrated substantial activity in relapsed or refractory disease, patients continue to face challenges associated with treatment resistance, relapse and the cumulative burden of successive therapies. This creates a demanding development environment in which high response rates are important, but insufficient on their own to establish long-term value.
Anito-cel, an investigational autologous CAR T-cell therapy targeting B-cell maturation antigen (BCMA), offers a distinctive example of receptor engineering. Its construct uses a synthetic d-domain antigen-binding moiety rather than the conventional antibody-derived binding architecture used in many CAR designs. The rationale is to develop a differentiated receptor structure while preserving potent recognition of BCMA-expressing myeloma cells.
In the Phase II iMMagine-1 study, updated results reported in 2025 showed substantial activity in heavily pretreated patients with relapsed or refractory multiple myeloma. Among 117 treated patients, the investigator-assessed overall response rate was 97%, and 68% achieved a complete response or stringent complete response. Among patients evaluable for minimal residual disease (MRD), 93% achieved MRD negativity at a sensitivity of 10-5. The study population had substantial prior treatment exposure, and all patients were refractory to their most recent line of therapy. These findings illustrate the potential of anito-cel to generate rapid, deep responses in a difficult-to-treat population.
The important interpretive distinction is between demonstrating activity and proving superiority. High response and MRD-negativity rates are encouraging, but they do not, by themselves, establish that a novel binding domain produces better long-term outcomes than other BCMA-directed CAR T-cell therapies. Differences in patient characteristics, follow-up duration, assessment methods and trial design also limit the reliability of cross-trial comparisons.
For ESMO 2026, the most consequential questions concern durability and treatment burden. Do deep responses continue to translate into sustained progression-free survival? Does the safety profile remain favourable as follow-up increases? And can the construct's design advantages be linked to outcomes that matter to patients, rather than remaining an attractive molecular distinction? Anito-cel therefore represents a broader test for next-generation CAR T-cell development: whether a rational engineering innovation can be validated through a clinically meaningful combination of response depth, durability and manageable toxicity.
3. The long-remission question: What can CD19-directed CAR T cells teach the field?
If anito-cel highlights the importance of receptor design, long-term follow-up of CD19-directed CAR T-cell therapy addresses an equally fundamental issue: how long can a cellular treatment continue to control a malignancy after a single infusion? This question is particularly relevant in B-cell non-Hodgkin lymphoma, where CAR T-cell therapy has become an established option for selected patients with relapsed or refractory disease. Initial response assessments capture whether a treatment works; long-term follow-up reveals whether that response can fundamentally change the patient's disease trajectory.
A 2026 report in the New England Journal of Medicine examining ten-year outcomes after tisagenlecleucel provides a striking illustration. Among 38 patients with relapsed or refractory B-cell non-Hodgkin lymphoma, the median follow-up was 10.1 years. No relapses were observed beyond 5.4 years after infusion. The estimated ten-year lymphoma-free survival was 32% in patients with large B-cell lymphoma and 47% in those with follicular lymphoma. These results emerged from a small cohort and should not be generalised to all CAR T-cell products or all patients; nevertheless, they provide compelling evidence that prolonged remission is possible in a subset of treated patients.
The clinical meaning extends beyond the duration of response. For patients who have exhausted multiple treatment options, sustained remission can mean a prolonged period without further lymphoma-directed therapy. For clinicians, it raises the question of how to identify patients most likely to experience lasting benefit. For developers, it makes the biology of persistence a central research priority.
CAR T-cell persistence is one possible contributor to long-term disease control, although persistence alone does not guarantee remission. The interaction between the engineered cells, the patient's immune system, the tumor's antigen expression and the disease's underlying biology is likely to be more complex than a single biomarker can capture. The long-term findings therefore invite a deeper examination of which cellular characteristics are associated with continued disease suppression and whether those characteristics can be deliberately optimised in future constructs.
For ESMO 2026, the broader lesson is that the success of CAR T-cell therapy cannot be fully judged at the first response assessment or even at the first year of follow-up. The field increasingly needs evidence that connects early response to the probability of remaining treatment-free years later.
4. From impressive response to durable benefit: The evidence gap that remains
Across multiple myeloma and B-cell lymphoma, CAR T-cell therapy has demonstrated that engineered immune cells can achieve outcomes that would have been difficult to anticipate from conventional treatment paradigms. Yet the next generation must address a more nuanced challenge: converting exceptional responses in some patients into predictable, sustained benefit across a broader population.
Three evidence priorities stand out.
First, response depth must be interpreted alongside durability. Complete response and MRD negativity are valuable indicators of disease clearance, particularly in multiple myeloma. However, the relationship between these measures and long-term progression-free or overall survival must be established through sufficiently mature follow-up. A high early response rate is a promising starting point, not a substitute for time-to-event outcomes.
Second, safety must be assessed as part of the product's overall value. Cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, cytopenias, infections and other complications can affect the treatment experience and the resources required for care. A differentiated construct becomes more compelling when its efficacy is accompanied by a manageable safety profile. Any suggestion of improved tolerability, however, requires careful interpretation against the study population, treatment protocol and available comparator evidence.
Third, the feasibility of treatment delivery remains inseparable from clinical performance. Autologous CAR T-cell therapy requires collection and manufacturing of the patient's cells, coordination of bridging treatment where needed, lymphodepletion and specialist monitoring. Manufacturing timelines, patient fitness, access to experienced centres and the risk of disease progression before infusion can influence who ultimately receives treatment. Innovation that improves efficacy but leaves these barriers unchanged may have a more limited impact on real-world outcomes than anticipated.
These considerations are particularly important as developers seek to position new CAR T-cell products in an increasingly competitive treatment landscape. Differentiation will require evidence that a therapy offers more than another high response rate: it must demonstrate a credible advantage in the quality, duration, safety or deliverability of treatment.
5. What ESMO 2026 could help clarify?
The CAR T-cell developments highlighted ahead of ESMO 2026 point to a field moving from proof of concept toward refinement. The central scientific challenge is no longer only whether engineered T cells can recognise cancer and induce remission. It is how the design of those cells, the biology of the disease and the clinical pathway combine to determine who benefits and for how long.
For next-generation constructs, the key issue is whether engineering advances translate into meaningful differences in clinical outcomes. For anito-cel, the focus is on whether its differentiated BCMA-binding architecture can support deep and durable responses with an acceptable safety profile in heavily pretreated multiple myeloma. For CD19-directed CAR T-cell therapy, long-term lymphoma outcomes reinforce the need to understand the biological features associated with sustained remission and to determine how reproducibly such outcomes can be achieved.
These are related but distinct questions. The anito-cel data address the performance of an investigational BCMA-directed product in a defined clinical setting; the ten-year lymphoma findings provide a long-horizon view of outcomes with tisagenlecleucel in a small cohort. Neither should be treated as direct evidence for the other. Together, however, they show why the next stage of CAR T-cell development must integrate construct-level innovation with mature clinical evidence.
The most informative conference discussions will therefore be those that look beyond isolated efficacy figures. Longer follow-up, patient-level outcomes, toxicity patterns, the relationship between cellular persistence and remission, and the feasibility of treatment delivery will all help determine whether next-generation CAR T-cell therapies are improving the overall treatment proposition.
Conclusion: The next generation must prove more than potency
CAR T-cell therapy is entering a phase in which innovation must be judged against increasingly demanding expectations. The ability to generate a deep response remains essential, but it is only one component of success. Durable disease control, manageable toxicity, predictable treatment delivery and the possibility of long-term remission are becoming equally important measures of progress. ESMO 2026 provides an opportunity to examine this shift through the lens of next-generation engineering, BCMA-directed therapy in multiple myeloma and long-term CD19-directed outcomes in lymphoma. The implications extend beyond individual candidates. They point towards a broader evolution in cellular therapy development: from proving that engineered cells can attack cancer to understanding how their design can produce lasting, clinically meaningful benefit.
Ultimately, the next breakthrough in CAR T-cell therapy may not be defined by the highest response rate reported at a conference. It may be defined by the ability to identify the patients most likely to achieve durable remission, understand why that remission occurs, and deliver the treatment safely and reliably enough for the benefit to be realised in routine practice.